胆囊癌新辅助治疗研究现状

doi:10.3969/j.issn.1009-976X.2021.03.002

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (03): 257-264.DOI: 10.3969/j.issn.1009-976X.2021.03.002

胆囊癌新辅助治疗研究现状

付佳禄, 雷建军, 张东, 耿智敏^*

西安交通大学第一附属医院肝胆外科,西安710061

通讯作者: *耿智敏,Email：gengzhimin@mail. xjtu. edu. cn
作者简介:耿智敏,医学博士,主任医师,博士生导师; 西安交通大学第一附属医院肝胆外科副主任; 主要研究方向为胆道肿瘤的临床及基础研究; 先后主持国家自然科学基金3项,陕西省重点研发计划项目1项,陕西省科技攻关项目2项,发表文章40余篇,SCI收录15篇;
中国医师协会外科医师分会胆道外科医师委员会常委、中华医学会外科学分会胆道外科学组委员、中国研究型医院学会数字医学临床外科专业委员会常委、中华外科青年医师学术研究社胆道外科研究组委员、国际肝胆胰协会中国分会胆道结石外科专家委员会常委、国际肝胆胰协会中国分会胆道肿瘤委员会委员、中国研究型医院学会加速康复外科专业委员会胆道学组委员、中国医疗保健国际交流促进会外科分会委员、陕西省医师协会胰胆疾病专业委员会副主任委员、陕西省医学会腔镜外科分会副主任委员、陕西省生物医学工程学会微创外科工程分会副主任委员、陕西省医学会外科学分会委员、陕西省抗癌协会肝胆胰肿瘤分会常委; 《世界华人消化杂志》《西部医学杂志》《岭南现代临床外科杂志》编委,《Chronic Diseases and Translational Medicine》通讯编委,《Chinese Medical Journal》《中华外科杂志》《世界华人消化杂志》《西安交通大学医学版》等杂志审稿专家。
基金资助:
国家自然科学基金（62076194）

Research status of neoadjuvant therapy for gallbladder cancer

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Online:2021-06-20 Published:2021-08-20

摘要/Abstract

摘要： 胆囊癌发病率逐年增高,目前治疗效果欠佳,为了改善胆囊癌患者的预后,有必要加强胆囊癌新辅助治疗研究。本文通过回顾已发表和正在开展的胆囊癌新辅助治疗研究,跟踪胆囊癌转化治疗（包括肿瘤化疗、放疗、免疫和靶向治疗）最新研究进展,对胆囊癌新辅助治疗研究现状进行阐述。

中图分类号:

R735.8

付佳禄, 雷建军, 张东, 耿智敏. 胆囊癌新辅助治疗研究现状[J]. 岭南现代临床外科, 2021, 21(03): 257-264.

FU Jia⁃lu, LEI Jian⁃jun, ZHANG Dong, GENG Zhi⁃min. Research status of neoadjuvant therapy for gallbladder cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(03): 257-264.

[1] 中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科专业委员会. 胆囊癌诊断和治疗指南(2019版)[J]. 中华外科杂志, 2020,58(4):243-251.
[2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[3] Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J]. Cancer Treat Rev, 2020,84:101936.
[4] Sahara K, Tsilimigras DI, Kikuchi Y, et al.Defining and predicting early recurrence after resection for gallbladder cancer[J]. Ann Surg Oncol, 2021,28(1):417-425.
[5] Jung S J, Woo SM, Park HK, et al.Patterns of initial disease recurrence after resection of biliary tract cancer[J]. Oncology, 2012,83(2):83-90.
[6] Hundal R, Shaffer EA.Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014,6:99-109.
[7] Rawla P, Sunkara T, Thandra KC, et al.Epidemiology of gallbladder cancer[J]. Clin Exp Hepatol, 2019,5(2):93-102.
[8] Tanvetyanon T, Clark JI, Campbell SC, et al.Neoadjuvant therapy: an emerging concept in oncology[J]. South Med J, 2005,98(3):338-344.
[9] Blumenthal GM, Bunn PJ, Chaft JE, et al.Current status and future perspectives on neoadjuvant therapy in lung cancer[J]. J Thorac Oncol, 2018,13(12):1818-1831.
[10] Madigan LI, Dinh P, Graham JD.Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines[J]. Breast Cancer Res, 2020,22(1):77.
[11] 梁廷波. 胰腺癌新辅助治疗的现状与展望[J]. 临床肝胆病杂志, 2019,35(5):19-25.
[12] Imyanitov EN, Yanus GA.Neoadjuvant therapy: theoretical, biological and medical consideration[J]. Chin Clin Oncol, 2018,7(6):55.
[13] Azizi AA, Lamarca A, Valle JW.Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer[J]. Chin Clin Oncol, 2019,8(4):14.
[14] 孟强劳, 王林, 耿智敏. 进展期胆囊癌新辅助化疗研究进展[J]. 中华肝胆外科杂志, 2017,23(11):789-792.
[15] 张子杰, 乔子耘, 冯浩,等. 系统治疗在肝癌术前新辅助治疗中应用进展[J]. 中国实用外科杂志, 2021,41(3):326-331.
[16] 中华医学会外科学分会胰腺外科学组, 中国研究型医院学会胰腺疾病专业委员会. 中国胰腺癌新辅助治疗指南(2020版)[J]. 中华外科杂志, 2020,58(9):657-667.
[17] Benson AB, D′Angelica MI, Abbott DE, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hepatobiliary Cancers Version 1.2021[J]. J Natl Compr Canc Netw,2021,17(4):302-310.
[18] Valle J, Wasan H, Palmer DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010,362(14):1273-1281.
[19] Okusaka T, Nakachi K, Fukutomi A, et al.Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J]. Br J Cancer, 2010,103(4):469-474.
[20] Chaudhari VA, Ostwal V, Patkar S, et al.Outcome of neoadjuvant chemotherapy in “locally advanced/borderline resectable” gallbladder cancer: the need to define indications[J]. HPB (Oxford), 2018,20(9):841-847.
[21] Creasy JM, Goldman DA, Dudeja V, et al.Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes[J]. J Am Coll Surg, 2017,224(5):906-916.
[22] Engineer R, Goel M, Chopra S, et al.Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm[J]. Ann Surg Oncol, 2016,23(9):3009-3015.
[23] Selvakumar VP, Zaidi S, Pande P, et al.Resection after neoadjuvant chemotherapy in advanced carcinoma of the gallbladder: a retrospective study[J]. Indian J Surg Oncol, 2015,6(1):16-19.
[24] Kato A, Shimizu H, Ohtsuka M, et al.Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study[J]. Ann Surg Oncol, 2013,20(1):318-324.
[25] Kato A, Shimizu H, Ohtsuka M, et al.Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery[J]. Ann Surg Oncol, 2015,22(Suppl 3):S1093-S1099.
[26] Gangopadhyay A, Nath P, Biswas J.Reduced dose intensity of chemotherapy may not lead to inferior palliation in locally advanced carcinoma of the gallbladder: an experience from a regional cancer centre in eastern india[J]. J Gastrointest Cancer, 2015,46(3):297-300.
[27] Agrawal S, Mohan L, Mourya C, et al.Radiological downstaging with neoadjuvant therapy in unresectable gallbladder cancer cases[J]. Asian Pac J Cancer Prev, 2016,17(4):2137-2140.
[28] Sirohi B, Mitra A, Jagannath P, et al.Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer[J]. Future Oncol, 2015,11(10):1501-1509.
[29] Fareed MM, DeMora L, Esnaola NF, et al. Concurrent chemoradiation for resected gallbladder cancers and cholangiocarcinoma[J]. J Gastrointest Oncol, 2018,9(4):762-768.
[30] Gruenberger B, Schueller J, Heubrandtner U, et al.Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study[J]. Lancet Oncol, 2010,11(12):1142-1148.
[31] Hakeem AR, Papoulas M, Menon KV.The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - a systematic review[J]. Eur J Surg Oncol, 2019,45(2):83-91.
[32] Lundgren L, Muszynska C, Ros A, et al.Management of incidental gallbladder cancer in a national cohort[J]. Br J Surg, 2019,106(9):1216-1227.
[33] Duffy A, Capanu M, Abou-Alfa GK, et al.Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)[J]. J Surg Oncol, 2008,98(7):485-489.
[34] Sharma A, Kalyan MB, Pal CS, et al.Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial[J]. Eur J Cancer, 2019,123:162-170.
[35] Ramaswamy A, Ostwal V, Pinninti R, et al.Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis[J]. J Hepatobiliary Pancreat Sci, 2017,24(5):262-267.
[36] Morizane C, Okusaka T, Mizusawa J, et al.Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial[J]. Ann Oncol, 2019,30(12):1950-1958.
[37] Shroff RT, Javle MM, Xiao L, et al.Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial[J]. JAMA Oncol, 2019,5(6):824-830.
[38] Lamarca A, Palmer DH, Wasan HS, et al.Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial[J]. Lancet Oncol, 2021,22(5):690-701.
[39] Le DT, Uram JN, Wang H, et al.PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015,372(26):2509-2520.
[40] Bang YJ, Doi T, Braud FD, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028 [J]. Eur J Cancer, 2015,51:S112.
[41] Piha-Paul SA, Oh DY, Ueno M, et al.Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020,147(8):2190-2198.
[42] Kim RD, Chung V, Alese OB, et al.A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020,6(6):888-894.
[43] Bang YJ, Ueno M, Malka D, et al.Pembrolizumab for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.[J]. J Clin Oncol, 2019,37(Suppl 15):4079.
[44] Klein O, Kee D, Nagrial A, et al.Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2020,6(9):1405-1409.
[45] Sun D, Ma J, Wang J, et al.Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer[J]. Cancer Immunol Immunother, 2019,68(9):1527-1535.
[46] Xie Y, Jiang Y, Yang XB, et al.Response of BRCA1-mutated gallbladder cancer to olaparib: a case report[J]. World J Gastroenterol, 2016,22(46):10254-10259.
[47] Ricci AD, Rizzo A, Bonucci C, et al.PARP inhibitors in biliary tract cancer: a new kid on the block?[J]. Medicines (Basel), 2020,7(9):54.
[48] Doebele RC, Drilon A, Paz-Ares L, et al.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020,21(2):271-282.
[49] Kheder ES, Hong DS.Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins[J]. Clin Cancer Res, 2018,24(23):5807-5814.
[50] Gruenberger B, Schueller J, Heubrandtner U, et al.Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study[J]. Lancet Oncol, 2010,11(12):1142-1148.
[51] Malka D, Cervera P, Foulon S, et al.Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial[J]. Lancet Oncol, 2014,15(8):819-828.
[52] Lee J, Park SH, Chang HM, et al.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary tract cancer: a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2012,13(2):181-188.
[53] Sun W, Patel A, Normolle D, et al.A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma[J]. Cancer, 2019,125(6):902-909.
[54] Kim RD, McDonough S, El-Khoueiry AB, et al. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer[J]. Eur J Cancer, 2020,130:219-227.
[55] Lau DK, Tay RY, Yeung YH, et al.Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study[J]. Br J Cancer, 2018,118(7):966-971.
[56] Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer[J]. J Hepatol, 2020,73(1):170-185.

胆囊癌新辅助治疗研究现状

Research status of neoadjuvant therapy for gallbladder cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

[1]	龙吟, 宋兴东, 张磊. 中晚期肝癌转化治疗中的几个焦点问题[J]. 岭南现代临床外科, 2022, 22(02): 115-119.
[2]	曾智豪, 何深. 三阴性乳腺癌新辅助治疗现状[J]. 岭南现代临床外科, 2022, 22(02): 205-209.
[3]	黄沾任, 宁金月, 李汉卿, 陈念平. 免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展[J]. 岭南现代临床外科, 2022, 22(01): 110-114.
[4]	丁陈陈, 宋兴东, 张磊. 肝脏外科医生眼中的2021 ASCO[J]. 岭南现代临床外科, 2021, 21(03): 265-271.
[5]	于小鹏, 童焕军, 汤朝晖. 联合治疗在胆道恶性肿瘤转化治疗中的应用探讨[J]. 岭南现代临床外科, 2021, 21(02): 133-137.
[6]	李永，谢明伟，石广滋，潘恒，李国照，易志龙*. 磁共振弥散加权成像在胆囊良、恶性病变鉴别诊断中的价值[J]. 岭南现代临床外科, 2019, 19(05): 541-543.
[7]	卓宪华，万云乐*. 积极监测：低风险甲状腺微小乳头状癌的一线治疗？[J]. 岭南现代临床外科, 2019, 19(05): 513-519.
[8]	王强，钟秉政，魏建昌. 老年人改良衰弱指数与新辅助治疗后行腹腔镜直肠癌患者围手术期并发症的相关性分析[J]. 岭南现代临床外科, 2019, 19(04): 392-395.
[9]	巨邦律陈永兵张维一于聪慧余昌中聂洪峰. 隐性胰胆逆流在胆囊癌早期诊断中的意义[J]. 岭南现代临床外科, 2016, 16(01): 21-23.
[10]	王浩熊沛. 胆囊息肉诊治的新进展[J]. 岭南现代临床外科, 2013, 13(03): 256-259.